Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: 2024 U.S. Biopharma Recap

The William Blair biopharma team recaps key financing and strategic transaction activity from 2024, a year defined by resilience and recovery. While 2024 started promisingly, macro headwinds resurfaced in the summer, and key healthcare nominations from the incoming presidential administration created uncertainty heading into 2025. Despite the volatility, the sector demonstrated its capacity for innovation and adaptability through robust public financing, creative deal structures, and a renewed focus on pipeline optimization.

Strength in biopharma financings was punctuated by increased crossover activity, steady IPO momentum in the second half of the year, and record secondary financing activity (follow-ons, PIPEs, and RDs). However, M&A in the sector slowed materially as major acquisitions were concentrated on the private side, with only 11 public M&A deals in 2024 completed for over $1 billion (compared to 21 in 2023). Moreover, 2024 was the first year since 2012 in which no acquisition in the sector was valued at greater than $10 billion.

Amid this shifting landscape, we remain optimistic for the sector in 2025 as lower interest rates, new FTC leadership (and thus looser reins on M&A), and a growing backlog of high-quality IPOs should fuel investor interest.

Our team is available if you have any questions or would like to discuss in further detail. We hope you have a great start to the New Year, and we look forward to catching up in 2025.

Complete the form below to download a copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Continental Disc Corporation Has Agreed to be Acquired by Baker Hughes

    William Blair acted as the lead financial advisor to Continental Disc Corporation, a portfolio company of Tinicum Incorporated, in connection with its pending sale to Baker Hughes (NASDAQ: BKR).

    Read more
  • Structural Concepts Corporation Has Agreed to be Acquired by Hoshizaki USA Holdings, Inc.

    William Blair acted as exclusive financial advisor to Structural Concepts Corporation, a portfolio company of Mason Wells, Inc., in connection with its pending sale to Hoshizaki USA Holdings, Inc.

    Read more
  • No ‘Pencils Down’ in Secondaries, Despite Tariff Shocks

    Confidence in the secondary market remains high—even if trade-related uncertainty remains—with investors saying they are “still open for business” and that they “won’t be going pencils down.”

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures